Search

Your search keyword '"Bobylev D"' showing total 264 results

Search Constraints

Start Over You searched for: Author "Bobylev D" Remove constraint Author: "Bobylev D"
264 results on '"Bobylev D"'

Search Results

4. Waitlist Stratification and Outcomes in Lung Transplantation for Severe Pulmonary Hypertension

7. Lung Transplantation in Patients with Severe Pulmonary Hypertension: a 13-Year Single-Center Experience.

9. (908) Does Donor-Recipient Sex Mismatch Have an Influence on Long Term Outcomes after Lung Transplantation? An Experience of a High Volume Center

10. (410) Perioperative Desensitization Changes the Plasma Cytokine Milieu in Lung Transplant Patients with Preformed Donor Specific Antibodies

11. 12-Year Experience with Postoperatively Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Arterial Hypertension

12. (101) Nine-Year Experience with Treatment of Early Detectable Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients

14. Nine-Year Experience with Perioperative Desensitization in Patients with Preformed Donor-Specific Antibodies in Lung Transplantation

15. Nine-Year Experience with Treatment of Early Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients

17. Bilateral Lung Transplantation for Pediatric Pulmonary Arterial Hypertension: Perioperative Management and One-Year Follow-up

20. Perioperative Desensitization with IgA- and IgM-Enriched Human Immunoglobulins Allows Safe Lung Transplantation in Patients with Preformed Donor Specific Antibodies

29. Eight-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Possible Subclinical and Clinical Antibody-Mediated Rejection after Lung Transplantation

30. Preformed Donor-Specific Antibodies in Lung Transplantation: Eight-Year Experience with Perioperative Desensitization Using IgA- and IgM-Enriched Human Immunoglobulins

32. Impact of Donor Quality on Recipient Outcomes in Lung Transplantation: 11-Year Single-Center Experience Using the Eurotransplant Lung Donor Score

33. Lifetime Endocarditis Risk with Congenital Heart Disease and Pulmonary Valve Prosthesis (PVP): Results from the German Registry for Congenital Heart Defects (CHD)

36. Seven-Year Clinical Results of an IgA-and IgM-Enriched Human Immunoglobulin-Based Therapy for Antibody-Mediated Rejection after Lung Transplantation

37. Fifteen-Year Single Center Experience with Lung Transplantation in Pediatric Patients Younger Than 12 Years Old

38. Influence of Donor-Recipient Age Mismatch in Young Lung Transplant Recipients

39. Preformed Donor Specific Antibodies in Lung Transplantation - Perioperative Desensitization Using IgA- and IgM-Enriched Immunoglobulins

40. 10-Year Experience with Postoperatively-Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Hypertension

41. Impact of Donor Quality on Recipient Outcomes in Lung Transplantation: 10-year Single-Center Experience Using the Eurotransplant Lung Donor Score

42. 10-Year Experience with Postoperatively Extended Intraoperative Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Severe Pulmonary Hypertension

43. Lung Transplantation in Pediatric Patients Younger than 12 Years: 15-Year Single-Center Experience

44. Seven-Year Clinical Results of AN IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Antibody-Mediated Rejection in Lung Transplantation

46. Influence of Donor-Recipient Age Mismatch in Young Lung Transplant Recipients

50. Ex Vivo Organ Perfusion for Heart Procurement in High-Risk Transplantations: A Multicenter Study

Catalog

Books, media, physical & digital resources